Unknown

Dataset Information

0

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.


ABSTRACT: Atezolizumab plus bevacizumab has been approved as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma (uHCC). This study was designed to assess the clinical impact of atezolizumab plus bevacizumab in uHCC patients. A total of 48 uHCC patients receiving atezolizumab plus bevacizumab were identified, including first-line, second-line, third-line, and later-line settings. In these patients, the median progression-free survival (PFS) was 5.0 months, including 5.0 months for the first-line treatment, not reached for the second-line treatment, and 2.5 months for the third line and later line treatment. The objective response rate and disease control rate to atezolizumab plus bevacizumab were 27.1% and 68.8%, respectively. The severity of most adverse events was predominantly grade 1-2, and most patients tolerated the toxicities. The ratios of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte (PLR) were used to predict PFS in these patients. The optimal cutoff values of NLR and PLR were 3 and 230, and NLR and PLR were independent prognostic factors for superior PFS in the univariate and multivariate analyses. Our study confirms the efficacy and safety of atezolizumab plus bevacizumab in uHCC patients in clinical practice and demonstrates the prognostic role of NLR and PLR for PFS in these patients.

SUBMITTER: Wang JH 

PROVIDER: S-EPMC8774110 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Wang Jing-Houng JH   Chen Yen-Yang YY   Kee Kwong-Ming KM   Wang Chih-Chi CC   Tsai Ming-Chao MC   Kuo Yuan-Hung YH   Hung Chao-Hung CH   Li Wei-Feng WF   Lai Hsiang-Lan HL   Chen Yen-Hao YH  

Cancers 20220111 2


Atezolizumab plus bevacizumab has been approved as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma (uHCC). This study was designed to assess the clinical impact of atezolizumab plus bevacizumab in uHCC patients. A total of 48 uHCC patients receiving atezolizumab plus bevacizumab were identified, including first-line, second-line, third-line, and later-line settings. In these patients, the median progression-free survival (PFS) was 5.0 months, including 5  ...[more]

Similar Datasets

| S-EPMC9737420 | biostudies-literature
| S-EPMC7317009 | biostudies-literature
| S-EPMC5895303 | biostudies-literature
| S-EPMC10386929 | biostudies-literature
| S-EPMC11507274 | biostudies-literature
| S-EPMC5535728 | biostudies-other
| S-EPMC10523973 | biostudies-literature
| S-EPMC11219835 | biostudies-literature
| S-EPMC7220521 | biostudies-literature